A panel of outside advisers to the US health regulator backed GSK s respiratory syncytial virus vaccine, setting it up for a race with rival Pfizer to become the first approved US shot against the disease.
A panel of outside advisers to the US health regulator recommended Pfizer Inc s respiratory syncytial virus vaccine, bringing it closer to becoming one of the first approved RSV shots for older adults in the United States.
Moderna said on Tuesday that its experimental mRNA vaccine for respiratory syncytial virus was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as cough and fever, in adults aged 60 and older.